Table 3.
Glycemic variations in male and female patients receiving low- and mid-mixed insulin analogues.
| Items | Male (52) | Female (50) | ||||
|---|---|---|---|---|---|---|
| Asp 30 | Lis 50 | p | Asp 30 | Lis 50 | p | |
| Duration > 10.0 | 25 (10.3, 38.8) | 19 (6, 31.3) | 0.14 | 34.5 (15, 50) | 22 (10.8, 46.3) | 0.28 |
| Duration < 3.9 | 0 (0, 4.8) | 0 (0, 0) | 0.01∗ | 0 (0, 0) | 0 (0, 0) | 0.86 |
| Duration 3.9-10 | 69.7 ± 21.1 | 79.1 ± 15.6 | 0.01∗ | 64.7 ± 23.7 | 70 ± 23.5 | 0.27 |
| AUC > 10.0 | 0.5 (0.1, 0.8) | 0.3 (0.1, 0.5) | 0.13 | 0.7 (0.2, 1.3) | 0.5 (0.1, 1.3) | 0.35 |
| AUC < 3.9 | 0 (0, 0) | 0 (0, 0) | 0.44 | 0 (0, 0) | 0 (0, 0) | 0.56 |
| AUC 3.9-10 | 19.8 ± 5.0 | 18.5 ± 4.2 | 0.16 | 21.6 ± 5.6 | 20.7 ± 5.3 | 0.42 |
| 24 hr MG | 8.5 ± 1.5 | 8.0 ± 1.2 | 0.1 | 9.0 ± 1.8 | 8.7 ± 1.7 | 0.35 |
| MAGE | 5.8 ± 2.2 | 5.6 ± 2.2 | 0.71 | 5.3 ± 2.2 | 5.1 ± 2.0 | 0.65 |
| CV% | 27.2 ± 9.0 | 27.1 ± 8.9 | 0.97 | 24.5 ± 7.2 | 24.5 ± 7.7 | 0.98 |
| SDMG | 2.3 ± 0.8 | 2.2 ± 0.7 | 0.45 | 2.2 ± 0.7 | 2.1 ± 0.7 | 0.62 |
∗ p < 0.05, male asp30 vs. male lis50. Duration > 10.0: time spent in glucose levels above 10.0 mmol/L (%); duration < 3.9: time spent in glucose levels less than 3.9 mmol/L (%); AUC > 10.0: the incremental area under curve of glucose > 10.0 mmol/L (mmol/L∗day); AOC < 3.9: the incremental area over curve of plasma glucose < 3.9 mmol/L (mmol/L∗day); AUC 3.9-10: the incremental area under the curve of glucose levels between 3.9 and 10 mmol/L; 24 hr MG: 24 hr mean glucose (mmol/L); MAGE: mean amplitude of glycemic excursions (mmol/L); CV%: the coefficient of variation; SDMG: standard deviation (mmol/L).